Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
Aidoc Receives FDA Breakthrough Status for Multi-Condition CT AI Triage
Aidoc has received FDA Breakthrough Device status for its AI solution that flags multiple critical conditions in CT scans.
•AI in Healthcare
FDA Seeks Real-World Performance Insights on AI Medical Devices
FDA calls for healthcare worker feedback to enhance monitoring of AI-enabled medical devices in real-world settings.
•Radiology Business
AI Tool Detects Elusive Epilepsy Lesions Missed by Radiologists
Researchers developed an AI tool that identifies focal cortical dysplasia on imaging, aiding diagnosis and surgical planning for epilepsy.